Summary
Fimasartan reduced blood pressure (BP) and albumin-creatinine ratio (ACR) in patients with or without metabolic syndrome; however, patients with metabolic syndrome at baseline and 3 months were at a greater risk of elevated ACR at 1 year. This article presents 3-month and 1-year data from a 3-year multicenter study designed to evaluate the effect of early correction of metabolic syndrome on organ damage for patients with hypertension [K-METS]. The design of this study has been published [Kim C et al. Pulse 2013].
- Cardiometabolic Disorder
- Cardiology Clinical Trials
- Hypertensive Disease
- Cardiometabolic Disorder
- Cardiology Clinical Trials
- Hypertensive Disease
- Cardiology
- © 2014 MD Conference Express®